The effects of highly active antiretroviral therapy on albuminuria in HIV-infected persons: Results from a randomized trial

Nephrology Dialysis Transplantation

Volumn 20, Issue 10, 2005, Pages 2237-2242

  Gupta, Samir K ^a   Parker, Robert A ^b   Robbins, Gregory K ^c   Dubé, Michael P ^a  

^a INDIANA UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Albuminuria; Antiretroviral therapy; Cardiovascular disease; Cardiovascular risk; HIV; Protease inhibitors

Indexed keywords

ALBUMIN; CD4 ANTIGEN; CREATININE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; URINALYSIS;

ADULT; ALBUMINURIA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CREATININE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 27144544602     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi053     Document Type: Article

References (20)

1. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003
2. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421-426
3. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869-1874
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486
5. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262
6. Jerico C, Knobel H, Montero M et al. Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 2005; 28: 132-137
7. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174
8. Ross MJ, Klotman PE. HIV-associated nephropathy. AIDS 2004; 18: 1089-1099
9. Robbins GK, De Grattola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349: 2293-2303
10. Dubé MP, Parker RA, Tebas P et al. Glucose metabolism, lipid, and body fat changes in anti retroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; in press
11. Jones CA, Francis ME, Eberhardt MS et al. Microalbuminuria in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2002; 39: 445-459
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
13. Levey AS, Green T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000; 11: 155A
14. Szczech LA, Hoover DR, Feldman JG et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004; 39: 1199-1206
15. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954
16. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1074
17. Duncombe C. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir. J Acquir Iminune Defic Syndr 2000; 24: 78-79
18. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type I. J Infect Dis 2002; 185: 456-462
19. Kimmel PL, Umana WO, Bosch JP. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol 1993; 39: 17-21
20. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dubé MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004; 61: 1-6